Articles from Sonoma Biotherapeutics, Inc.

 

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointment of Lisa Taylor Ash, JD, to the company's executive management team as Chief Legal Officer and Secretary. Ms. Ash joins Sonoma Biotherapeutics as a proven biotech executive with deep expertise in public and private biotech companies across the entire product lifecycle, most recently serving as Chief Operating Officer and General Counsel at Shape Therapeutics.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster presentation at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress, taking place in Barcelona on June 11-14, 2025.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, taking place in New Orleans May 13-17, 2025.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, announced today that it has received a $45 million milestone payment from Regeneron Pharmaceuticals, Inc., under the terms of its active collaboration to discover, develop and commercialize engineered Treg therapies for autoimmune diseases.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg therapy product candidate for the treatment of rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2023, taking place in San Diego, California from November 10-15th.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg product candidate for the treatment of hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA). The meeting takes place October 13-15th in Phoenix, Arizona.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointments of Joseph R. Arron, M.D., Ph.D., as Chief Scientific Officer and Mark D. Eisner, M.D., MPH, as Chief Medical Officer. Sonoma Bio Co-founder and Chief Scientific Officer, Fred Ramsdell, Ph.D., will retire and remain a member of the Company’s Scientific Advisory Board.

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s industry-leading VelociSuite® technologies for the discovery and characterization of fully human antibodies and T cell receptors (TCRs) with Sonoma Biotherapeutics’ pioneering approach to developing and manufacturing gene-modified Treg cell therapies.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be presenting key data at the American College of Rheumatology (ACR) Convergence 2022 Scientific Sessions highlighting preclinical data from the company’s autologous Treg therapy for the treatment of rheumatoid arthritis (RA). The meeting takes place November 10th–14th, 2022 at the Pennsylvania Convention Center in Philadelphia, PA.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointment of Jessica Stitt as Chief Financial Officer. Stitt has over 20 years of healthcare finance, strategy, and leadership experience and has participated in the execution of nearly $2 billion in corporate financing transactions. She will join Sonoma Biotherapeutics’ executive leadership team and oversee the company’s finance, accounting, information technology, communications, and investor relations functions.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced that it has entered into a lease agreement to develop an approximately 83,000 square-foot Research and Development (R&D) and Manufacturing Center to expand its operations in Seattle and complement its existing R&D enterprise in South San Francisco. The state-of-the-art Center will support the R&D and manufacturing of Sonoma Bio’s pipeline of gene-modified Treg therapies for autoimmune and inflammatory diseases at scale.

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH, to its Board of Directors.